Busquets Sílvia, Toledo Míriam, Sirisi Sònia, Orpí Marcel, Serpe Roberto, Coutinho Joana, Martínez Raquel, Argilés Josep M, López-Soriano Francisco J
Cancer Research Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona.
Exp Ther Med. 2011 Jul;2(4):731-735. doi: 10.3892/etm.2011.260. Epub 2011 Apr 28.
Cancer cachexia occurs in the majority of cancer patients before death, and it is responsible for the death of 22% of cancer patients. One of the most relevant characteristics of cachexia is that of asthenia, which reflects significant muscle wasting noted in cachectic cancer patients The aim of the present study was to assess whether the β(2)-adrenergic agonist formoterol is associated with an improvement in physiological parameters such as grip force and total physical activity in cachetic rats. Administration of the β(2)-agonist formoterol (0.3 mg/kg for 7 days) in rats bearing Yoshida AH-130 ascites hepatoma tumors, a model which induces a strong loss of both body and muscle weight, resulted in a significant reversal of the muscle wasting process, as reflected by individual muscle weights. The anti-wasting effects of the drug were also observed in terms of total physical activity and grip force, thus resulting in an improvement in physical performance in cachectic tumor-bearing rats.
癌症恶病质在大多数癌症患者临终前都会出现，它导致了22%的癌症患者死亡。恶病质最相关的特征之一是虚弱，这反映了恶病质癌症患者明显的肌肉萎缩。本研究的目的是评估β(2)-肾上腺素能激动剂福莫特罗是否与恶病质大鼠的生理参数改善有关，如握力和总体身体活动。在携带吉田AH-130腹水肝癌肿瘤的大鼠中给予β-激动剂福莫特罗（0.3 mg/kg，持续7天），该模型会导致体重和肌肉重量显著下降，个体肌肉重量反映出肌肉萎缩过程得到了显著逆转。从总体身体活动和握力方面也观察到了该药物的抗消瘦作用，从而使恶病质荷瘤大鼠的身体表现得到改善。
